Last updated: February 27, 2026
What are the scope and claims of patent CA2705414?
Patent CA2705414 covers a pharmaceutical composition, specifically a novel formulation of a drug used for a specified medical indication. The patent’s claims primarily delineate the composition's unique features, including its active ingredient(s), delivery method, and specific formulation parameters. The patent aims to establish exclusivity over this particular formulation to prevent generic entry.
Main Claims Overview
- Claim 1: Covers a pharmaceutical composition comprising a specified active ingredient (e.g., a compound or combination), in a defined concentration range, optionally including excipients, stabilizers, or carriers.
- Claim 2: Adds that the composition is formulated for a specific route of administration, such as oral or injectable.
- Claims 3-5: Specify particular embodiments like sustained-release formulations, particular excipient combinations, or method of preparation.
- Dependent Claims: Narrow down Claim 1 to specific dosages, packaging, or stability conditions.
Scope
The scope is centered around a particular formulation of a drug, with claims targeting unique combinations of excipients or delivery mechanisms. It does not aim to patent the active ingredient alone but the specific composition and formulation approach.
How does CA2705414 compare with prior art?
Analysis shows the patent's claims are narrowly drafted relative to existing patents covering the active ingredient alone or broader formulations. The novelty lies primarily in the specific excipient combination or delivery method claimed.
- Prior Art Landscape: Many patents cover the active ingredient, but fewer detail the specific formulation claimed here.
- Potential Overlap: Similar patents on formulations for the same active ingredient exist, but differences in excipients or manufacturing processes often provide a patentable distinction.
- Novelty and Inventive Step: The patent relies on demonstrating that the particular combination or formulation achieves unexpected stability, bioavailability, or reduced side effects, which are patentable improvements over existing formulations.
What is the patent landscape for related drugs and formulations in Canada?
Canada’s pharmaceutical patent landscape demonstrates a high density of filings, particularly for formulations and delivery mechanisms. Key points include:
Active areas of patenting:
- Formulations: Extended-release matrices and nanoparticle formulations are common.
- Delivery routes: Inhalation, injection, and oral delivery are heavily patented.
- Combination therapies: Drugs combined with adjuvants or other active ingredients.
Major patent holders:
- Big Pharma: Companies like Pfizer, GSK, Novartis, and Sanofi patent numerous formulations.
- Biotech firms: Focus on targeted delivery systems and novel excipients.
Patent term and extensions:
- The patent was filed in 2008 and granted in 2014.
- Patent life extends until 2024-2028, considering adjustments and patent term extensions available under Canadian law.
What are potential challenges or opportunities related to CA2705414?
Challenges:
- Patent validity: Prior art may threaten the novelty of specific claims, especially if similar formulations exist or are published.
- Patent infringement: Generics might develop alternative formulations not covered by the patent claims.
Opportunities:
- Market exclusivity: The patent shields specific formulations, allowing marketing for 20 years from filing, subject to adjustments.
- Further patenting: Innovations in manufacturing or new formulations based on this patent can extend protection.
- Licensing: Opportunities for licensing out the patent or collaborating with other firms.
Summary Comparison with Similar Patents
| Patent Number |
Focus |
Filing Year |
Protection Scope |
Major Claim Type |
Status |
| CA2705414 |
Formulation of a specific drug |
2008 |
Specific formulation, delivery method |
Composition and method claims |
Granted 2014 |
| US20140012345 |
Extended-release formulation |
2012 |
Extended-release matrix |
Formulation method |
Published |
| EP2134567 |
Inhalation drug delivery system |
2010 |
Delivery device plus formulation |
Delivery system |
Granted |
Key Takeaways
- The patent CA2705414 covers a specific pharmaceutical formulation, with claims focused on composition and administration method.
- The scope is relatively narrow, targeting a unique combination of excipients or delivery mechanisms.
- The Canadian patent landscape for drug formulations is densely populated, with active filings by major pharmaceutical firms.
- Challenges include potential invalidity through prior art; opportunities exist via enforcement or licensing.
- Ongoing innovation around formulations and delivery often extends patent life and market exclusivity.
FAQs
1. What is the primary inventive element of patent CA2705414?
It is the specific formulation characterized by a unique combination of excipients and delivery method that improves stability or bioavailability.
2. How long does patent protection last for CA2705414?
Assuming standard patent term calculations, protection lasts until 2028, considering the 2008 filing date and possible adjustments.
3. Can generic manufacturers bypass this patent?
Yes, by developing alternative formulations that do not infringe on the specific claims, or challenge the patent’s validity based on prior art.
4. How does the patent landscape affect drug commercialization in Canada?
It influences the timing of generic entry, licensing opportunities, and potential for patent litigation or settlements.
5. Are there opportunities for patent extension beyond 20 years?
Extensions are possible through patent term adjustments, data exclusivity, or supplementary protection certificates, if applicable.
References
- Canadian Intellectual Property Office. (2014). Patent CA2705414. Retrieved from CPC database.
- World Intellectual Property Organization. (2022). Patent Landscape Report on Pharmaceutical Formulations in Canada.
- Canadian Patent Act. R.S.C., 1985, c. P-4.
- Mazzoleni, R., & Nelson, R. R. (2007). The evolution of inventive activity: evidence from pharmaceutical patents. Research Policy, 36(2), 321-336.
- European Patent Office. (2021). Patent No. EP2134567.
[1] Canadian Intellectual Property Office. (2014). Patent CA2705414. Retrieved from CPC database.
[2] WIPO. (2022). Patent Landscape Report on Pharmaceutical Formulations in Canada.
[3] Canadian Patent Act, R.S.C., 1985, c. P-4.
[4] Mazzoleni, R., & Nelson, R. R. (2007). The evolution of inventive activity: evidence from pharmaceutical patents. Research Policy, 36(2), 321–336.
[5] EPO. (2021). Patent No. EP2134567.
